t140 peptide profile

T140 peptide: a strong anti-hiv agent; amino acid sequence in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

ID Source	ID
PubMed CID	16130395
SCHEMBL ID	15987184
MeSH ID	M0300486

Synonym
gtpl853
[l-3-(2-naphthyl)-alanine3]-t134
229030-20-0
l-arginine, l-arginyl-l-arginyl-3-(2-naphthalenyl)-l-alanyl-l-cysteinyl-l-tyrosyl-l-arginyl-l-lysyl-d-lysyl-l-prolyl-l-tyrosyl-l-arginyl-n5-(aminocarbonyl)-l-ornithyl-l-cysteinyl-, cyclic (4-13)-disulfide
t-140
T140 ,
t 140
h-arg-ala-nal-cys-tyr-arg-lys-dlys-pro-tyr-arg-cit-cys-arg-oh
t140 peptide
SCHEMBL15987184
mfcd00677792
Q27088913
DTXSID80177446
CS-0674594
HY-P4810

Assay ID	Title	Year	Journal	Article
AID1346821	Human CXCR4 (Chemokine receptors)	1998	Biochemical and biophysical research communications, Dec-30, Volume: 253, Issue:3	A low-molecular-weight inhibitor against the chemokine receptor CXCR4: a strong anti-HIV peptide T140.
AID1346821	Human CXCR4 (Chemokine receptors)	2002	The Journal of biological chemistry, Jul-05, Volume: 277, Issue:27	A point mutation that confers constitutive activity to CXCR4 reveals that T140 is an inverse agonist and that AMD3100 and ALX40-4C are weak partial agonists.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	1 (2.04)	18.2507
2000's	38 (77.55)	29.6817
2010's	8 (16.33)	24.3611
2020's	2 (4.08)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	0 (0.00%)	5.53%
Reviews	4 (8.16%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	45 (91.84%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Classes	Roles
4-aminopyridine [no description available]	2.06	1	aminopyridine; aromatic amine	avicide; orphan drug; potassium channel blocker
erythrosine Fluoresceins: A family of spiro(isobenzofuran-1(3H),9'-(9H)xanthen)-3-one derivatives. These are used as dyes, as indicators for various metals, and as fluorescent labels in immunoassays.	2.06	1
2-(4-morpholinyl)-8-phenyl-4h-1-benzopyran-4-one 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one: specific inhibitor of phosphatidylinositol 3-kinase; structure in first source	2.05	1	chromones; morpholines; organochlorine compound	autophagy inhibitor; EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor; geroprotector
alanine Alanine: A non-essential amino acid that occurs in high levels in its free state in plasma. It is produced from pyruvate by transamination. It is involved in sugar and acid metabolism, increases IMMUNITY, and provides energy for muscle tissue, BRAIN, and the CENTRAL NERVOUS SYSTEM.. alanine : An alpha-amino acid that consists of propionic acid bearing an amino substituent at position 2.	2.01	1	alanine zwitterion; alanine; L-alpha-amino acid; proteinogenic amino acid; pyruvate family amino acid	EC 4.3.1.15 (diaminopropionate ammonia-lyase) inhibitor; fundamental metabolite
methionine Methionine: A sulfur-containing essential L-amino acid that is important in many body functions.. methionine : A sulfur-containing amino acid that is butyric acid bearing an amino substituent at position 2 and a methylthio substituent at position 4.	2	1	aspartate family amino acid; L-alpha-amino acid; methionine zwitterion; methionine; proteinogenic amino acid	antidote to paracetamol poisoning; human metabolite; micronutrient; mouse metabolite; nutraceutical
phenylalanine Phenylalanine: An essential aromatic amino acid that is a precursor of MELANIN; DOPAMINE; noradrenalin (NOREPINEPHRINE), and THYROXINE.. L-phenylalanine : The L-enantiomer of phenylalanine.. phenylalanine : An aromatic amino acid that is alanine in which one of the methyl hydrogens is substituted by a phenyl group.	2.46	2	amino acid zwitterion; erythrose 4-phosphate/phosphoenolpyruvate family amino acid; L-alpha-amino acid; phenylalanine; proteinogenic amino acid	algal metabolite; EC 3.1.3.1 (alkaline phosphatase) inhibitor; Escherichia coli metabolite; human xenobiotic metabolite; micronutrient; mouse metabolite; nutraceutical; plant metabolite; Saccharomyces cerevisiae metabolite
arginine Arginine: An essential amino acid that is physiologically active in the L-form.. arginine : An alpha-amino acid that is glycine in which the alpha-is substituted by a 3-guanidinopropyl group.	2.04	1	arginine; glutamine family amino acid; L-alpha-amino acid; proteinogenic amino acid	biomarker; Escherichia coli metabolite; micronutrient; mouse metabolite; nutraceutical
framycetin Framycetin: A component of NEOMYCIN that is produced by Streptomyces fradiae. On hydrolysis it yields neamine and neobiosamine B. (From Merck Index, 11th ed). framycetin : A tetracyclic antibacterial agent derived from neomycin, being a glycoside ester of neamine and neobiosamine B.	2.04	1	aminoglycoside	allergen; antibacterial drug; Escherichia coli metabolite
citrulline citrulline : The parent compound of the citrulline class consisting of ornithine having a carbamoyl group at the N(5)-position.	2	1	amino acid zwitterion; citrulline	Daphnia magna metabolite; EC 1.14.13.39 (nitric oxide synthase) inhibitor; Escherichia coli metabolite; human metabolite; micronutrient; mouse metabolite; nutraceutical; plant metabolite; protective agent; Saccharomyces cerevisiae metabolite
vidarabine adenine arabinoside : A purine nucleoside in which adenine is attached to arabinofuranose via a beta-N(9)-glycosidic bond.	2.02	1	beta-D-arabinoside; purine nucleoside	antineoplastic agent; bacterial metabolite; nucleoside antibiotic
azides Azides: Organic or inorganic compounds that contain the -N3 group.. azide : Any nitrogen molecular entity containing the group -N3.	2.06	1	pseudohalide anion	mitochondrial respiratory-chain inhibitor
zidovudine Zidovudine: A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by an azido group. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. The compound is a potent inhibitor of HIV replication, acting as a chain-terminator of viral DNA during reverse transcription. It improves immunologic function, partially reverses the HIV-induced neurological dysfunction, and improves certain other clinical abnormalities associated with AIDS. Its principal toxic effect is dose-dependent suppression of bone marrow, resulting in anemia and leukopenia.. zidovudine : A pyrimidine 2',3'-dideoxyribonucleoside compound having a 3'-azido substituent and thymine as the nucleobase.	2	1	azide; pyrimidine 2',3'-dideoxyribonucleoside	antimetabolite; antiviral drug; HIV-1 reverse transcriptase inhibitor
plerixafor plerixafor: a bicyclam derivate, highly potent & selective inhibitor of HIV-1 & HIV-2. plerixafor : An azamacrocycle consisting of two cyclam rings connected by a 1,4-phenylenebis(methylene) linker. It is a CXCR4 chemokine receptor antagonist and a hematopoietic stem cell mobilizer. It is used in combination with grulocyte-colony stimulating factor (G-CSF) to mobilize hematopoietic stem cells to the perpheral blood for collection and subsequent autologous transplantation in patients with non-Hodgkin's lymphoma and multiple myeloma.	3.82	11	azacycloalkane; azamacrocycle; benzenes; crown amine; secondary amino compound; tertiary amino compound	anti-HIV agent; antineoplastic agent; C-X-C chemokine receptor type 4 antagonist; immunological adjuvant
1,4,7-triazacyclononane-n,n',n''-triacetic acid 1,4,7-triazacyclononane-N,N',N''-triacetic acid: structure given in first source	2.13	1
tak 779 [no description available]	2.04	1
2-naphthylalanine 2-naphthylalanine: structure in first source	2.01	1
vmip-ii vMIP-II: encoded by Kaposi's sarcoma-associated herpesvirus; chemokine that blocks calcium mobilization induced by endogenous chemokines; binds to both CC and CXC chemokine receptors; amino acid sequence in first source; GenBank U67775	2	1
fludarabine [no description available]	2.02	1	purine nucleoside
cystine [no description available]	3.1	1
4-azidophenylalanine 4-azidophenylalanine: RN given refers to (L)-isomer. 4-azido-L-phenylalanine : A 4-azidophenylalanine that has L-configuration. It is used as a bioorthogonal click-chemistry reagent.. 4-azidophenylalanine : A phenylalanine derivative that is phenylalanine substituted by an azido group at position 4.	2.06	1
aluminum Aluminum: A metallic element that has the atomic number 13, atomic symbol Al, and atomic weight 26.98.	2.13	1	boron group element atom; elemental aluminium; metal atom
4-benzoylphenylalanine 4-benzoylphenylalanine: structure in first source; do not confuse with N-benzoylphenylalanine	2.46	2
t22 protein, synthetic T22 protein, synthetic: a synthetic protein with anti-human immunodeficiency virus activity; do not confuse with T22 antigen, a class I histocompatibility antigen	3.5	2
tachyplesin peptide, tachypleus tridentatus tachyplesin peptide, Tachypleus tridentatus: isolated from the hemocytes of the horseshoe crab (Tachypleus tridentatus); cationic peptide; 17 amino acid residues given in first source	1.99	1
tn14003 TN14003: synthetic antagonist 14-mer peptide inhibiting metastasis in an animal model	2.75	3
alx40 4c N-alpha-acetyl-nona-D-arginine amide acetate: inhibits HIV-1 by acting as competitive inhibitor of HIV Tat protein; cxcr4 receptor antagonist; structure in first source	2.69	3
tc14012 TC14012: small peptide inhibitor of the CXCR4	2.02	1

Condition	Relationship Strength	Studies
Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.	3.4	2
Arthritis, Degenerative [description not available]	2.15	1
Osteoarthritis A progressive, degenerative joint disease, the most common form of arthritis, especially in older persons. The disease is thought to result not from the aging process but from biochemical changes and biomechanical stresses affecting articular cartilage. In the foreign literature it is often called osteoarthrosis deformans.	2.15	1
Metastase [description not available]	2.73	3
Neoplasm Metastasis The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.	2.73	3
Infections, Lentivirus [description not available]	2.05	1
Cat Diseases Diseases of the domestic cat (Felis catus or F. domesticus). This term does not include diseases of the so-called big cats such as CHEETAHS; LIONS; tigers, cougars, panthers, leopards, and other Felidae for which the heading CARNIVORA is used.	2.05	1
Kahler Disease [description not available]	3.36	2
Osteolysis Dissolution of bone that particularly involves the removal or loss of calcium.	2.96	1
Multiple Myeloma A malignancy of mature PLASMA CELLS engaging in monoclonal immunoglobulin production. It is characterized by hyperglobulinemia, excess Bence-Jones proteins (free monoclonal IMMUNOGLOBULIN LIGHT CHAINS) in the urine, skeletal destruction, bone pain, and fractures. Other features include ANEMIA; HYPERCALCEMIA; and RENAL INSUFFICIENCY.	3.36	2
Rhabdomyosarcoma 2 [description not available]	2.05	1
Rhabdomyosarcoma, Alveolar A form of RHABDOMYOSARCOMA occurring mainly in adolescents and young adults, affecting muscles of the extremities, trunk, orbital region, etc. It is extremely malignant, metastasizing widely at an early stage. Few cures have been achieved and the prognosis is poor. Alveolar refers to its microscopic appearance simulating the cells of the respiratory alveolus. (Holland et al., Cancer Medicine, 3d ed, p2188)	2.05	1
Rhabdomyosarcoma, Embryonal A form of RHABDOMYOSARCOMA arising primarily in the head and neck, especially the orbit, of children below the age of 10. The cells are smaller than those of other rhabdomyosarcomas and are of two basic cell types: spindle cells and round cells. This cancer is highly sensitive to chemotherapy and has a high cure rate with multi-modality therapy. (From Holland et al., Cancer Medicine, 3d ed, p2188)	2.05	1
Cell Transformation, Neoplastic Cell changes manifested by escape from control mechanisms, increased growth potential, alterations in the cell surface, karyotypic abnormalities, morphological and biochemical deviations from the norm, and other attributes conferring the ability to invade, metastasize, and kill.	2.05	1
Benign Neoplasms [description not available]	2.05	1
Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.	2.05	1
Pregnancy The status during which female mammals carry their developing young (EMBRYOS or FETUSES) in utero before birth, beginning from FERTILIZATION to BIRTH.	2.45	2
Acute Lymphoid Leukemia [description not available]	2.01	1
Leukemia, Pre-B-Cell [description not available]	2.01	1
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma A leukemia/lymphoma found predominately in children and adolescents and characterized by a high number of lymphoblasts and solid tumor lesions. Frequent sites involve LYMPH NODES, skin, and bones. It most commonly presents as leukemia.	2.01	1
Precursor Cell Lymphoblastic Leukemia-Lymphoma A neoplasm characterized by abnormalities of the lymphoid cell precursors leading to excessive lymphoblasts in the marrow and other organs. It is the most common cancer in children and accounts for the vast majority of all childhood leukemias.	2.01	1
Breast Cancer [description not available]	2.01	1
Cancer of Lung [description not available]	2.01	1
Breast Neoplasms Tumors or cancer of the human BREAST.	2.01	1
Lung Neoplasms Tumors or cancer of the LUNG.	2.01	1
Rheumatoid Arthritis [description not available]	2.02	1
Arthritis, Rheumatoid A chronic systemic disease, primarily of the joints, marked by inflammatory changes in the synovial membranes and articular structures, widespread fibrinoid degeneration of the collagen fibers in mesenchymal tissues, and by atrophy and rarefaction of bony structures. Etiology is unknown, but autoimmune mechanisms have been implicated.	2.02	1
Cancer of Prostate [description not available]	2.02	1
Prostatic Neoplasms Tumors or cancer of the PROSTATE.	2.02	1
B-Cell Chronic Lymphocytic Leukemia [description not available]	2.02	1
Leukemia, Lymphocytic, Chronic, B-Cell A chronic leukemia characterized by abnormal B-lymphocytes and often generalized lymphadenopathy. In patients presenting predominately with blood and bone marrow involvement it is called chronic lymphocytic leukemia (CLL); in those predominately with enlarged lymph nodes it is called small lymphocytic lymphoma. These terms represent spectrums of the same disease.	2.02	1
Angiogenesis, Pathologic [description not available]	2.03	1
Gammapathy, Monoclonal [description not available]	2.03	1
Paraproteinemias A group of related diseases characterized by an unbalanced or disproportionate proliferation of immunoglobulin-producing cells, usually from a single clone. These cells frequently secrete a structurally homogeneous immunoglobulin (M-component) and/or an abnormal immunoglobulin.	2.03	1
Infections, Plasmodium [description not available]	2.01	1
Malaria A protozoan disease caused in humans by four species of the PLASMODIUM genus: PLASMODIUM FALCIPARUM; PLASMODIUM VIVAX; PLASMODIUM OVALE; and PLASMODIUM MALARIAE; and transmitted by the bite of an infected female mosquito of the genus ANOPHELES. Malaria is endemic in parts of Asia, Africa, Central and South America, Oceania, and certain Caribbean islands. It is characterized by extreme exhaustion associated with paroxysms of high FEVER; SWEATING; shaking CHILLS; and ANEMIA. Malaria in ANIMALS is caused by other species of plasmodia.	2.01	1

t140 peptide

Description

Cross-References

Synonyms (15)

Bioassays (2)

Research

Studies (49)

Market Indicators

Research Demand Index: 11.97

Study Types

t140 peptide

Description

Cross-References

Synonyms (15)

Bioassays (2)

Research

Studies (49)

Market Indicators

Research Demand Index: 11.97

Study Types

Related Drugs (27)

Related Conditions (36)